Ask AI

Redefining Success: Individualizing HBV Care Slides

Antiviral therapies for hepatitis B virus (HBV) infection effectively suppress viral replication, but rarely lead to loss of HBsAg or functional cure. Recently, experts proposed a stepwise framework of individualized endpoints to redefine HBV treatment ranging from durable on-treatment suppression to partial cure to functional cure, based on patient-specific factors and biomarker profiles. These slides summarize the current state of HBV treatment and monitoring, and explore ways to individualize therapy goals with new and upcoming agents.

Individualizing HBV Care Slides

Activity Information

Released: November 06, 2026